{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:34:02Z","timestamp":1787693642040,"version":"build-2784847793"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myasthenic crisis (MC) is a life-threatening condition for patients with myasthenia gravis (MG). Seronegative patients represent around 10\u201315% of MG, but data on outcome of seronegative MCs are lacking. We performed a subgroup analysis of patients who presented with MC with either acetylcholine-receptor-antibody-positive MG (AChR-MG) or seronegative MG between 2006 and 2015 in a retrospective German multicenter study. We identified 15 seronegative MG patients with 17 MCs and 142 AChR-MG with 159 MCs. Seronegative MCs were younger (54.3\u2009\u00b1\u200914.5 vs 66.5\u2009\u00b1\u200916.3\u00a0years; <jats:italic>p<\/jats:italic>\u2009=\u20090.0037), had a higher rate of thymus hyperplasia (29.4% vs 3.1%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0009), and were more likely to be female (58.8% vs 37.7%; <jats:italic>p<\/jats:italic>\u2009=\u20090.12) compared to AChR-MCs. Time between diagnosis of MG and MC was significantly longer in seronegative patients (8.2\u2009\u00b1\u20097.6 vs 3.1\u2009\u00b1\u20094.4\u00a0years; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). We found no differences in duration of mechanical ventilation (16.2\u2009\u00b1\u200915.8 vs 16.5\u2009\u00b1\u200915.9\u00a0days; <jats:italic>p<\/jats:italic>\u2009=\u20090.94) and length of stay at intensive care unit (17.6\u2009\u00b1\u200915.2 vs 17.8\u2009\u00b1\u200915.4\u00a0days; <jats:italic>p<\/jats:italic>\u2009=\u20090.96), or in-hospital mortality (11.8% vs. 10.1%; <jats:italic>p<\/jats:italic>\u2009=\u20090.69). We conclude that MC in seronegative MG affects younger patients after a longer period of disease, but that crisis treatment efficacy and outcome do not differ compared to AChR-MCs.<\/jats:p>","DOI":"10.1007\/s00415-022-11023-z","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:08:58Z","timestamp":1649329738000},"page":"3904-3911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Seronegative myasthenic crisis: a multicenter analysis"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-6711","authenticated-orcid":false,"given":"Philipp","family":"Mergenthaler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning R.","family":"Stetefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dohmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sch\u00f6nenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"B\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan T.","family":"Gerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen B.","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Reichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fuhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Alberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Schneider-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Dunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Steinbrecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf A.","family":"Linker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Angstwurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8254-8616","authenticated-orcid":false,"given":"Bernhard","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for The German Myasthenic Crisis Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"issue":"5","key":"11023_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12(5):259\u2013268. https:\/\/doi.org\/10.1038\/nrneurol.2016.44","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"11023_CR2","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Sch\u00f6nenberger S, B\u00f6sel J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR, German Myasthenic Crisis Study Group (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94(3):e299\u2013e313. https:\/\/doi.org\/10.1212\/WNL.0000000000008688","journal-title":"Neurology"},{"issue":"5","key":"11023_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/wnl.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, Brannagan TH, Fink ME, Rowland LP (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48(5):1253\u20131260. https:\/\/doi.org\/10.1212\/wnl.48.5.1253","journal-title":"Neurology"},{"key":"11023_CR4","doi-asserted-by":"publisher","first-page":"885066620967646","DOI":"10.1177\/0885066620967646","volume":"25","author":"K Angstwurm","year":"2020","unstructured":"Angstwurm K, Vidal A, Stetefeld H, Dohmen C, Mergenthaler P, Kohler S, Sch\u00f6nenberger S, B\u00f6sel J, Neumann U, Lee DH, Gerner ST, Huttner HB, Thieme A, Dunkel J, Roth C, Schneider H, Schimmel E, Reichmann H, Fuhrer H, Berger B, Kleiter I, Schneider-Gold C, Alberty A, Zinke J, Schalke B, Steinbrecher A, Meisel A, Neumann B (2020) Early tracheostomy is associated with shorter ventilation time and duration of ICU stay in patients with myasthenic crisis-a multicenter analysis. J Intensive Care Med 25:885066620967646. https:\/\/doi.org\/10.1177\/0885066620967646","journal-title":"J Intensive Care Med"},{"issue":"12","key":"11023_CR5","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","volume":"268","author":"N K\u00f6nig","year":"2021","unstructured":"K\u00f6nig N, Stetefeld HR, Dohmen C, Mergenthaler P, Kohler S, Sch\u00f6nenberger S, B\u00f6sel J, Lee DH, Gerner ST, Huttner HB, Schneider H, Reichmann H, Fuhrer H, Berger B, Zinke J, Alberty A, Kleiter I, Schneider-Gold C, Roth C, Dunkel J, Steinbrecher A, Thieme A, Schlachetzki F, Linker RA, Angstwurm K, Meisel A, Neumann B (2021) MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J Neurol 268(12):4824\u20134833. https:\/\/doi.org\/10.1007\/s00415-021-10603-9","journal-title":"J Neurol"},{"issue":"18","key":"11023_CR6","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72(18):1548\u20131554. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a41211","journal-title":"Neurology"},{"issue":"1","key":"11023_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/ene.12115","volume":"21","author":"J Spillane","year":"2014","unstructured":"Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard RS (2014) Myasthenia gravis\u2013treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis. Eur J Neurol 21(1):171\u2013173. https:\/\/doi.org\/10.1111\/ene.12115","journal-title":"Eur J Neurol"},{"issue":"7","key":"11023_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","volume":"22","author":"A Ramos-Fransi","year":"2015","unstructured":"Ramos-Fransi A, Rojas-Garc\u00eda R, Segovia S, M\u00e1rquez-Infante C, Pardo J, Coll-Cant\u00ed J, Jeric\u00f3 I, Illa I (2015) Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 22(7):1056\u20131061. https:\/\/doi.org\/10.1111\/ene.12703","journal-title":"Eur J Neurol"},{"key":"11023_CR9","unstructured":"Wiendl H (2015). Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"issue":"Pt 7","key":"11023_CR10","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131(Pt 7):1940\u20131952. https:\/\/doi.org\/10.1093\/brain\/awn092","journal-title":"Brain"},{"issue":"6","key":"11023_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","volume":"139","author":"S Hoffmann","year":"2020","unstructured":"Hoffmann S, Harms L, Schuelke M, R\u00fcckert JC, Goebel HH, Stenzel W, Meisel A (2020) Complement deposition at the neuromuscular junction in seronegative myasthenia gravis. Acta Neuropathol 139(6):1119\u20131122. https:\/\/doi.org\/10.1007\/s00401-020-02147-5","journal-title":"Acta Neuropathol"},{"issue":"8059","key":"11023_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s0140-6736(78)90073-9","volume":"1","author":"A Vincent","year":"1978","unstructured":"Vincent A, Scadding GK, Thomas HC, Newsom-Davis J (1978) In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet 1(8059):305\u2013307. https:\/\/doi.org\/10.1016\/s0140-6736(78)90073-9","journal-title":"Lancet"},{"issue":"3","key":"11023_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.20386","volume":"57","author":"MI Leite","year":"2005","unstructured":"Leite MI, Str\u00f6bel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57(3):444\u2013448. https:\/\/doi.org\/10.1002\/ana.20386","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11023-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11023-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11023-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T04:40:59Z","timestamp":1655872859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11023-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["11023"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11023-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philipp Mergenthaler is on the Advisory Board of HealthNextGen Inc. and has equity interest in the company, within the scope of the present work, but not directly related; Henning R. Stetefeld reports no disclosures; Christian Dohmen reports no disclosures; Siegfried Kohler reports no disclosures; Silvia Sch\u00f6nenberger reports no disclosures; Julian B\u00f6sel reports personal fees from Medtronic, personal fees from Zoll, personal fees from Boehringer Ingelheim, personal fees from Sedana Medical, personal fees from PCORI, outside the submitted work. Stefan T. Gerner reports no disclosures; Hagen B. Huttner reports personal fees from Daiichi Sanyko, grants and personal fees from Novartis, grants and personal fees from UCB Pharma, grants and personal fees from Portola Pharmaceuticals, personal fees from Bayer AG, personal fees from Boehringer Ingelheim, personal fees from Prediction BioSciences, outside the submitted work; Hauke Schneider reports no disclosures; Heinz Reichmann reports no disclosures; Hannah Fuhrer reports no disclosures; Benjamin Berger received travel grants and\/or training expenses from Bayer Vital GmbH, Ipsen Pharma GmbH, Novartis, Biogen GmbH, Merck Serono GmbH, and Genzyme, as well as lecture fees from Ipsen Pharma GmbH, Alexion Pharma Germany GmbH, Merck Serono GmbH, Sanofi Genzyme, and Roche Pharma AG outside the submitted work; Jan Zinke reports no disclosures; Anke Alberty reports no disclosures; Ingo Kleiter reports personal fees from Biogen, personal fees from Novartis, personal fees from Merck, personal fees from Sanofi Genzyme, personal fees from Roche, personal fees from Mylan, personal fees from Alexion, personal fees from Celgene, grants and personal fees from Chugai, personal fees from IQVIA, outside the submitted work; Christiane Schneider-Gold has received consulting and\/or speaker's honoraria from Alexion Pharmaceuticals, Amicus Therapeutics, Bayer Schering, CSL Behring, Gr\u00fcnenthal, Hormosan, Lupin Pharmaceuticals, and TEVA outside the submitted work; Christian Roth reports no disclosures; Juliane Dunkel reports no disclosures; Andreas Steinbrecher reports no disclosures; Andrea Thieme reports no disclosures; De-Hyung Lee reports no disclosures; Ralf Linker reports no disclosures; Klemens Angstwurm reports no disclosures; Andreas Meisel reports personal fees from Hormosan, personal fees from Grifols, grants and personal fees from Alexion, personal fees from Argnx, personal fees from Novartis, personal fees from UCB, grants from Octapharma, outside the submitted work. Bernhard Neumann reports no disclosures. The authors declare no financial or other conflicts of interest related to the manuscript. Statistical analysis was conducted by Dr. Bernhard Neumann, University Medical Center Regensburg\/Donau-Isar-Klinikum Deggendorf.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local ethic committees and institutional review boards of the participating centers approved the study based on the central vote of the ethics committee at University of Regensburg (No. 15\u2013101-0259). Due to the retrospective character of the study, patient`s consent was not necessary according to the decisions of the ethic committees and institutional review boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}